BioInvent International AB (OSTO:BINV) ROE % Adjusted to Book Value : -17.31% (As of Dec. 2024)

View and export this data going back to 2001. Start your Free Trial

What is BioInvent International AB ROE % Adjusted to Book Value?

BioInvent International AB's ROE % for the quarter that ended in Dec. 2024 was -49.50%. BioInvent International AB's PB Ratio for the quarter that ended in Dec. 2024 was 2.86. BioInvent International AB's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was -17.31%.

BioInvent International AB ROE % Adjusted to Book Value Historical Data

The historical data trend for BioInvent International AB's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioInvent International AB ROE % Adjusted to Book Value Chart

BioInvent International AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-6.88

-13.33

-2.20

-23.85

-13.67

BioInvent International AB Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-30.13	-26.96	-20.95	-11.68	-17.31

Competitive Comparison of BioInvent International AB's ROE % Adjusted to Book Value

For the Biotechnology subindustry, BioInvent International AB's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioInvent International AB's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioInvent International AB's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where BioInvent International AB's ROE % Adjusted to Book Value falls into.

Save Embed

;

Save Embed

;

BioInvent International AB ROE % Adjusted to Book Value Calculation

BioInvent International AB's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-39.11%	/	2.86
	=	-13.67%

BioInvent International AB's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-49.50%	/	2.86
	=	-17.31%

BioInvent International AB ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of BioInvent International AB's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

BioInvent International AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioInvent International AB (OSTO:BINV) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

0H22:UK BIX0:Germany

Address

Ideongatan 1, Lund, SWE, SE-223 70

Website

https://www.bioinvent.com

BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's own clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.

BioInvent International AB Headlines

No Headlines